Publications by authors named "Matthew Squires"

Claim this Profile
B
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.
Paul E Oberstein, Andressa Dias Costa, Emily A Kawaler, Victoire Cardot-Ruffino, Osama E Rahma, Matthew Squires

Cancer Immunol Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying predictive biomarkers for repetitive transcranial magnetic stimulation response in depression patients with explainability.
Matthew Squires, Xiaohui Tao, Soman Elangovan, Raj Gururajan, Xujuan Zhou

Comput Methods Programs Biomed· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep learning and machine learning in psychiatry: a survey of current progress in depression detection, diagnosis and treatment.
Matthew Squires, Xiaohui Tao, Soman Elangovan, Raj Gururajan, Xujuan Zhou

Brain Inform· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor.
Patrick Schöffski, Yemarshet Gebreyohannes, Thomas Van Looy, Paul Manley, Joseph D Growney, Matthew Squires

Biomedicines· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, Georgina V Long, Keith T Flaherty, Matthew Squires

Lancet Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Reinhard Dummer, Jan C Brase, James Garrett, Catarina D Campbell, Eduard Gasal, Matthew Squires

Lancet Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clean, robust alkali sources by intercalation within highly oriented pyrolytic graphite.
Rudolph N Kohn, Matthew S Bigelow, Mary Spanjers, Benjamin K Stuhl, Brian L Kasch, Matthew B Squires

Rev Sci Instrum· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Oncology-Where to from Here? A Global Inquiry into the Perspectives of Radiation Oncology Professionals in Light of the Growing Cancer Epidemic.
Matthew Squires, Sonja Cheers

J Med Imaging Radiat Sci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Static beam tomotherapy as an optimisation method in whole-breast radiation therapy (WBRT).
Matthew Squires, Yunfei Hu, Mikel Byrne, Ben Archibald-Heeren, Sonja Cheers

J Med Radiat Sci· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Timothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Matthew Squires

Mol Cancer Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy.
Antonino Musolino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H Barrios, Matthew Squires

Breast Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Feasibility Study on the Use of TomoTherapy Megavoltage Computed Tomography Images for Palliative Patient Treatment Planning.
Yunfei Hu, Mikel Byrne, Ben Archibald-Heeren, Matthew Squires, Amy Teh

J Med Phys· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
Pamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, Lesley Gilmour, Matthew Squires

Cell Cycle· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
Paola Guglielmelli, Giada Rotunno, Costanza Bogani, Carmela Mannarelli, Laura Giunti, Matthew Squires

Br J Haematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification and characterization of a STAT5 gene signature in hematologic malignancies.
Dmitriy Sonkin, Michael Palmer, Xianhui Rong, Kim Horrigan, Catherine H Regnier, Matthew Squires

Cancer Biomark· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Matthew I Milowsky, Christian Dittrich, Ignacio Durán, Satinder Jagdev, Frederick E Millard, Matthew Squires

Eur J Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen-Chuan Ou, Daniel Castellano, Matthew Squires

Clin Cancer Res· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Paola Guglielmelli, Flavia Biamonte, Giada Rotunno, Valentina Artusi, Lucia Artuso, Matthew Squires

Blood· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Robert J Motzer, Camillo Porta, Nicholas J Vogelzang, Cora N Sternberg, Cezary Szczylik, Matthew Squires

Lancet Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Wenqing Qi, Xiaobing Liu, Laurence S Cooke, Daniel O Persky, Thomas P Miller, Matthew Squires

Int J Cancer· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
Matthew Squires, George Ward, Gordan Saxty, Valerio Berdini, Anne Cleasby

Mol Cancer Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atom chips on direct bonded copper substrates.
Matthew B Squires, James A Stickney, Evan J Carlson, Paul M Baker, Walter R Buchwald

Rev Sci Instrum· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Ruriko Tanaka, Matthew S Squires, Shinya Kimura, Asumi Yokota, Rina Nagao

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Mark A Dawson, Jayne E Curry, Kelly Barber, Philip A Beer, Brent Graham, Matthew S Squires

Br J Haematol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Matthew S Squires, Laurence Cooke, Victoria Lock, Wenqing Qi, E Jonathan Lewis

Mol Cancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis